Switch theme
Sign up to access all valuation multiples
TTY Biopharm Co Ltd is engaged in the manufacturing and marketing of pharmaceuticals and chemical drugs. The company's operating segments includes Oncology Business unit, Health Care Business unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business unit segment. It generates maximum revenue from the Oncology segment. Geographically, it derives a majority of revenue from Taiwan and also has a presence in European and Other Countries. Some of its products include Algitab, Alginos, Sulfin, Metacin, Cepiro, Brosym, Colimycin, Cubicin, and others.
1960
553
LTM Revenue $180M
LTM EBITDA n/a
$486M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
TTY Biopharm has a last 12-month revenue of $180M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, TTY Biopharm achieved revenue of $178M and an EBITDA of $64.2M.
TTY Biopharm expects next 12-month revenue of XXX and NTM EBITDA of XXX
See TTY Biopharm valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $166M | $178M | XXX | XXX | XXX |
| Gross Profit | $91.2M | $99.3M | XXX | XXX | XXX |
| Gross Margin | 55% | 56% | XXX | XXX | XXX |
| EBITDA | $50.0M | $64.2M | XXX | XXX | XXX |
| EBITDA Margin | 30% | 36% | XXX | XXX | XXX |
| Net Profit | $33.0M | $34.1M | XXX | XXX | XXX |
| Net Margin | 20% | 19% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, TTY Biopharm's stock price is TWD 70 (or $2).
TTY Biopharm has current market cap of TWD 17.4B (or $526M), and EV of TWD 16.1B (or $486M).
See TTY Biopharm trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $486M | $526M | XXX | XXX | XXX | XXX | $0.17 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, TTY Biopharm has market cap of $526M and EV of $486M.
TTY Biopharm's trades at 2.7x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate TTY Biopharm's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for TTY Biopharm and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $486M | XXX | XXX | XXX |
| EV/Revenue | 2.7x | XXX | XXX | XXX |
| EV/EBITDA | 7.6x | XXX | XXX | XXX |
| P/E | 12.0x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 13.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpTTY Biopharm's NTM/LTM revenue growth is 3%
TTY Biopharm's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, TTY Biopharm's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate TTY Biopharm's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for TTY Biopharm and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 36% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 28% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 39% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 22% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 8% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 5% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 34% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
TTY Biopharm acquired XXX companies to date.
Last acquisition by TTY Biopharm was XXXXXXXX, XXXXX XXXXX XXXXXX . TTY Biopharm acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was TTY Biopharm founded? | TTY Biopharm was founded in 1960. |
| Where is TTY Biopharm headquartered? | TTY Biopharm is headquartered in Taiwan. |
| How many employees does TTY Biopharm have? | As of today, TTY Biopharm has 553 employees. |
| Is TTY Biopharm publicy listed? | Yes, TTY Biopharm is a public company listed on ROCO. |
| What is the stock symbol of TTY Biopharm? | TTY Biopharm trades under 4105 ticker. |
| When did TTY Biopharm go public? | TTY Biopharm went public in 2001. |
| Who are competitors of TTY Biopharm? | Similar companies to TTY Biopharm include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of TTY Biopharm? | TTY Biopharm's current market cap is $526M |
| What is the current revenue of TTY Biopharm? | TTY Biopharm's last 12-month revenue is $180M. |
| What is the current EV/Revenue multiple of TTY Biopharm? | Current revenue multiple of TTY Biopharm is 2.7x. |
| What is the current revenue growth of TTY Biopharm? | TTY Biopharm revenue growth between 2023 and 2024 was 7%. |
| Is TTY Biopharm profitable? | Yes, TTY Biopharm is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
